Top 5 Target	Count

PRKAB1 x SGLT2	1
Tubulin	1
AT1R(Angiotensin II Receptor Type 1)	1
Na/K-ATPase(Sodium/potassium-transporting ATPase)	1
HIF-PHs(Hypoxia-inducible factor prolyl hydroxylase)	1

Drugs associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Roxadustat

Target

HIF-PHs

Mechanism

HIF-PHs inhibitors

Active Org.

Astellas Pharma Global Development, Inc. [+7]

Originator Org.

FibroGen, Inc.

Active Indication

Anemia [+6]

Inactive Indication

Neoplasms [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date17 Dec 2018

Empagliflozin/metformin Hydrochloride

Target

PRKAB1 x SGLT2

Mechanism

PRKAB1 activators [+1]

Active Org.

Boehringer Ingelheim Pharmaceuticals, Inc. [+5]

Originator Org.

Boehringer Ingelheim GmbH

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

EU [+3]

First Approval Date27 May 2015

Vonoprazan Fumarate

Target

Na/K-ATPase

Mechanism

Na/K-ATPase inhibitors

Active Org.

Takeda Pharmaceuticals Korea Co., Ltd. [+5]

Originator Org.

Takeda Pharmaceutical Co., Ltd.

Active Indication

Non-erosive gastro-esophageal reflux disease [+12]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date26 Dec 2014

Clinical Trials associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

CTR20241796

/ CompletedPhase 1

枸橼酸托法替布缓释片（11 mg）健康人体生物等效性研究

[Translation] Bioequivalence study of tofacitinib citrate extended-release tablets (11 mg) in healthy volunteers

主要目的：本研究以浙江尖峰药业有限公司生产并持有的枸橼酸托法替布缓释片（规格：11 mg）为受试制剂，按生物等效性研究的有关规定，以Pfizer Pharmaceuticals LLC生产的枸橼酸托法替布缓释片（规格：11 mg，商品名：尚杰®/Xeljanz®）为参比制剂，评估受试制剂和参比制剂在空腹/餐后条件下给药后的生物等效性。次要目的：观察受试制剂枸橼酸托法替布缓释片和参比制剂枸橼酸托法替布缓释片（尚杰®/Xeljanz®）在健康受试者中的安全性。

[Translation]

Main purpose: This study used the tofacitinib citrate extended-release tablets (specification: 11 mg) produced and owned by Zhejiang Jianfeng Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, the tofacitinib citrate extended-release tablets (specification: 11 mg, trade name: Shangjie®/Xeljanz®) produced by Pfizer Pharmaceuticals LLC were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: Observe the safety of the test preparation tofacitinib citrate extended-release tablets and the reference preparation tofacitinib citrate extended-release tablets (Shangjie®/Xeljanz®) in healthy subjects.

Start Date17 Jun 2024

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

CTR20241615

/ CompletedPhase 1

美阿沙坦钾片随机、开放、两周期、两序列、双交叉健康受试者空腹及餐后单次给药人体生物等效性试验

[Translation] A randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Asartan Potassium Tablets in healthy subjects after single administration on an empty stomach or after a meal

主要目的：以健康受试者为试验对象，采用随机、开放、两周期、两序列、双交叉试验设计，考察健康受试者空腹及餐后单次口服浙江尖峰药业有限公司生产的美阿沙坦钾片（受试制剂，规格：80mg）与Takeda Ireland Ltd.生产（Takeda Pharma A/S 持证）的美阿沙坦钾片（参比制剂，商品名：易达比®，规格：80mg）后美阿沙坦的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价其空腹及餐后状态下的生物等效性，为受试制剂的生产注册申请提供依据。次要目的：评价美阿沙坦钾片受试制剂和参比制剂（商品名：易达比®）在健康受试者中的安全性。

[Translation]

Main purpose: With healthy subjects as the test subjects, a randomized, open, two-period, two-sequence, double-crossover design was used to investigate the in vivo time course of mesartan after a single oral administration of mesartan potassium tablets (test preparation, specification: 80 mg) produced by Zhejiang Jianfeng Pharmaceutical Co., Ltd. and mesartan potassium tablets (reference preparation, trade name: Edabi®, specification: 80 mg) produced by Takeda Ireland Ltd. (licensed by Takeda Pharma A/S) to healthy subjects on an empty stomach and after a meal, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in the fasting and after-meal state, and provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of mesartan potassium tablets (trade name: Edabi®) in healthy subjects.

Start Date03 Jun 2024

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

CTR20241379

/ CompletedPhase 1

浙江尖峰药业有限公司研制的富马酸伏诺拉生片与原研参比制剂在中国健康受试者中进行的单中心、随机、开放、两制剂、空腹和餐后、单次给药、两周期、双交叉设计的生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, fasting and postprandial, single-dose, two-period, double-crossover bioequivalence study of vonoprazan fumarate tablets developed by Zhejiang Jianfeng Pharmaceutical Co., Ltd. and the original reference preparation in healthy Chinese subjects

以浙江尖峰药业有限公司研制的富马酸伏诺拉生片（规格：20 mg）为受试制剂，生产厂家为Takeda Pharmaceutical Company Limited的富马酸伏诺拉生片（商品名：沃克®/Vocinti®，规格：20 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The vonoprazan fumarate tablets (specification: 20 mg) developed by Zhejiang Jianfeng Pharmaceutical Co., Ltd. were used as the test preparation, and the vonoprazan fumarate tablets (trade name: Walker®/Vocinti®, specification: 20 mg) produced by Takeda Pharmaceutical Company Limited were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date17 May 2024

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

12 Nov 2024·Journal of Chemical Education

An Online Mini-Game for Novices to Understand the Basics of a Schlenk Line

Author: Zhang, Yan ; Wu, Changhui ; Wang, Mengjiao ; Wu, Ruizhen ; Zhang, Xiaojin ; Dong, Ying ; Lv, Sihong

A Schlenk line is a feasible way to implement air-sensitive exptl. techniques.However, due to limited resources and safety concerns, many colleges-especially those with higher student-teacher ratios-do not provide practical experiments using Schlenk lines in undergraduate lab courses.This may prevent students from fully meeting the skill requirements for scientific research or industrial jobs.To overcome this gap, a free mini-game, Learn Schlenk Line (LSL), was developed based on a popular social media app to help beginners learn Schlenk line techniques.This game introduces an interactive way to learn background knowledge and understand the general apparatus, basic operation and application scenarios for Schlenk lines without face-to-face assistance.It also helps players to improve their ability to identify hazards and understand the significance of standardized operations.Research, including control groups, showed that students who played LSL performed better in answering operational questions.For the delivery of college curricula or other training activities, LSL could help participants gain an intuitive understanding of Schlenk systems before entering a wet lab and assist novices in self-evaluating their operational understanding during hands-on practice.For undergraduates, even if hands-on activities are not part of their coursework, LSL could also help them perform more successfully in their follow-up wet-lab training.

13 Oct 2023·ACS Applied Polymer Materials

High Strength Magnetic/Temperature Dual-Response Hydrogels for Applications as Actuators

Author: Wen, Yabing ; Liang, Yanbo ; Ji, Yun ; Xiu, Huijuan ; Kozliak, Evguenii ; Du, Xiaoyun ; Li, Jinbao ; Zhao, Haizhi ; Li, Na ; Wu, Minzhe

01 May 2023·Bioresource Technology

Selective degradation of hemicellulose and lignin for improving enzymolysis efficiency via pretreatment using deep eutectic solvents

Article

Author: Zhu, Hongxiang ; Huo Conceptulization, Dan ; Liu, Ying ; Yang, Qiulin ; Zhang, Fengshan ; Fang, Guigan ; Sun, Yuekai

Deep eutectic solvents (DESs) with different acidity and alkalinity were applied for biomass pretreatment, and the conditions were optimized by response surface methodology. The results showed that lactic acid/betaine hydrochloride had the optimal pretreatment efficiency, where the removal rates of hemicellulose and lignin came up to 89% and 73%, and the enzymolysis efficiency was as high as 92%. Furthermore, eight types of chloride salts with different valence states were introduced into the DESs as the third component. The chloride salts could improve the pretreatment efficiency and positively correlated with the metal valence state. Specifically, AlCl₃ was significantly superior in improving the pretreatment efficiency, where the enzymolysis efficiency reached 96% due to the destruction of crystalline region and the esterification of partial cellulose. Therefore, it is proposed that adding highly valent metal salts to acidic DESs has higher pretreatment and enzymatic efficiency.

News (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

17 Feb 2018

·www.bioportfolio.com

Green Tea PolyphenolIndia Market Status and Trend Report 20132023 [Report Updated: 12022018] Prices from USD $2980

Report Summary Green Tea PolyphenolIndia Market Status and Trend Report 20132023 offers a comprehensive analysis on Green Tea Polyphenol industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include: Whole India and Regional Market Size of Green Tea Polyphenol 20132017, and development forecast 20182023 Main market players of Green Tea Polyphenol in India, with company and product introduction, position in the Green Tea Polyphenol market Market status and development trend of Green Tea Polyphenol by types and applications Cost and profit status of Green Tea Polyphenol, and marketing status Market growth drivers and challenges The report segments the India Green Tea Polyphenol market as: India Green Tea Polyphenol Market: Regional Segment Analysis Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 20132023: North India Northeast India East India South India West India India Green Tea Polyphenol Market: Product Type Segment Analysis Consumption Volume, Average Price, Revenue, Market Share and Trend 20132023: Flavanols Anthocyanins Flavonoids Flavonols Phenoliacids India Green Tea Polyphenol Market: Application Segment Analysis Consumption Volume and Market Share 20132023; Downstream Customers and Market Analysis Functional Foods Cosmetics Dietary Supplements Functional Beverages Others India Green Tea Polyphenol Market: Players Segment Analysis Company and Product introduction, Green Tea Polyphenol Sales Volume, Revenue, Price and Gross Margin: DSM Tianjin Jianfeng Natural Products DuPontDanisco Amax NutraSource Naturex Bioserae Prinova FutureCeuticals Indena Ajinomoto OmniChem Natural Specialty Seppic Frutarom In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

100 Deals associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

Phase 1 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Roxadustat ( HIF-PHs )	chronic renal failure anemia More	Phase 1
Azilsartan Kamedoxomil ( AT1R )	Hypertension More	Phase 1
Empagliflozin/metformin Hydrochloride ( PRKAB1 x SGLT2 )	Diabetes Mellitus, Type 2 More	Phase 1
Vonoprazan Fumarate ( Na/K-ATPase )	Dyspepsia More	Phase 1
Deoxypodophyllotoxin ( Tubulin )	Advanced Malignant Solid Neoplasm More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis